Echosens’ FibroScan® Selected by NASHNET Centers of Excellence Network: Pilot Study Underway Identifies Patients with Progressive Non-Alcoholic Fatty Liver Disease

WALTHAM, Mass.–(BUSINESS WIRE)–Echosens,
an innovative high-technology company offering the FibroScan®
family of products, today announces that the NASH
Network
(NASHNET), a global Centers of Excellence Network
represented by leading healthcare systems in collaboration with The
Kinetix Group
, is utilizing FibroScan in a pilot study to
appropriately identify patients with progressive non-alcoholic fatty
liver disease (NAFLD). With a goal to create an optimal care delivery
model, NASHNET will utilize FibroScan and associated screening tests in
primary care, endocrinology and bariatric clinics.

“An estimated 30 percent of individuals in the U.S. are affected by
NAFLD, with most patients undiagnosed,” says Douglas Dieterich, MD,
Director of the Institute for Liver Medicine, Mount Sinai Health System.
“Given this high prevalence of disease, cost effective risk
stratification strategies need to be proven and adopted to target more
effective assessments and interventions for those patients at greater
risk of advancing liver disease.”

Dr. Dieterich points to FibroScan as a rapid, noninvasive quantification
tool at the point of care that may enable efficient and cost-effective
early screening and subsequent disease identification.

“This is essential to improve NAFLD disease management and reduce the
disease impact on overall patient health and the healthcare system as a
whole,” he continues.

In collaboration with Echosens, NASHNET will collect and analyze data on
6,500 patients over a one-year period. This real-world evidence study is
designed to identify cost effective patient flows to screen, diagnose,
and manage patients with NAFLD and NASH. To accomplish this goal, the
NASHNET steering committee is recommending that FibroScan devices be
placed within their primary care and/or diabetic clinics.

Principal NASHNET pilot study investigators include:

  • Mount Sinai Health System: Amon Asgharpour, M.D., Assistant Professor,
    Icahn School of Medicine at Mount Sinai; Amreen Dinani, M.D.,
    Assistant Professor, Icahn School of Medicine at Mount Sinai; Douglas
    Dieterich, M.D., Director of the Institute for Liver Medicine, Mount
    Sinai Health System
  • Baylor College of Medicine: Norman Sussman, M.D., Associate Professor
    of Surgery, Baylor College of Medicine
  • Ochsner Medical Center: Dr. George Therapondos, Head of Hepatology,
    Ochsner MultiOrgan Transplant Institute, Dr. Nigel Girgrah, Chief
    Wellness Officer, Ochsner Health System, Medical Director, Multi-Organ
    Transplant Institute, Ochsner Medical Center
  • Cedars-Sinai Medical Center: Mazen Noureddin, M.D., Director,
    Cedars-Sinai Fatty Liver Program, Cedars Sinai Medical Center
  • Northwestern Feinberg School of Medicine: Mary Rinella, M.D.,
    Professor of Medicine, Director, Northwestern Fatty Liver Program,
    Northwestern University Feinberg School of Medicine
  • New York University Langone: Viviana Figueroa Diaz, M.D., Assistant
    Professor, New York Langone
  • Methodist Health System: Parvez S Mantry M.D., AGAF, FAASLD, CPE,
    Executive Medical Director, Methodist Health System Clinical Research
    Institute, Medical Director, Hepatobiliary Tumor Program, The Liver
    Institute at Methodist Dallas Medical Center

Dieterich concludes, “Our aim is to assess cost effective screening,
diagnosis and management approaches that leverage the unique ability of
FibroScan to rapidly quantify stiffness and estimate liver fat, and to
make the technology available where patients receive their care. The
study will evaluate care models that utilize FibroScan in conjunction
with routine lab tests, lipidomic and metabolic profiles, magnetic
resonance elastography (MRE), exploratory biomarkers, and morphometric
analysis. The objective is to improve identification of patients with
progressive NAFLD and reserve more costly assessments to those patients
at greater risk for mortality and morbidity associated with the disease.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology
company offering a full range of products and services supporting
physicians in their assessment and management of patients with chronic
liver diseases. FibroScan® is supported by over 2,000 peer reviewed
publications. http://www2.echosens.com/AboutFibroScan.

About The Kinetix Group

The Kinetix Group is a boutique care delivery consultancy that combines
deep health care experience, diverse clinical expertise, and an
expansive network of healthcare leaders to provide guidance and
execution of care delivery strategies. Kinetix works with life science,
health system and payer partners across the healthcare ecosystem to
develop and implement real world solutions that improve care, drive
better population health, and deliver sustainable value to those they
serve.

About NASHNET

NASHNET, a Kinetix Group-led network founded in 2017, aims to improve
non-alcoholic fatty liver disease (NAFLD) care delivery by promoting
collaboration, innovation, best practice sharing, and the development of
real-world evidence across leading delivery systems. NASHNET aims to
create standardization and systematization of care models that address
major NAFLD/NASH gaps including patient identification and
stratification, referrals and intervention methodologies, care
coordination processes, and patient and provider education from primary
care through hepatology.

Contacts

Media:
Mary Spardel
CPR Communications
[email protected]
201.641.1911
x 22